Low affinity FC gamma r deficient mice
Patent Information
- Application Number
- HK42026126195
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2009-12-21
- Filing Date
- 2026-07-15
- Publication Date
- 2026-09-11
Abstract
Description
(19) *EP004706388A2* (11) EP 4 706 388 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 11.03.2026 Bulletin 2026 / 11 (21) Application number: 25225090.7 (22) Date of filing: 17.12.2010 (51) International Patent Classification (IPC): A01K 67 / 027 (2024.01) (52) Cooperative Patent Classification (CPC): A01K 67 / 0276; A01K 67 / 0278; C07K 14 / 70535; A01K 2207 / 15; A01K 2217 / 072; A01K 2217 / 075; A01K 2217 / 15; A01K 2227 / 105; A01K 2267 / 0387 (84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (30) Priority: 21.12.2009 US 28856209 P (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 19154880.9 / 3 498 730 18154933.8 / 3 336 102 10791039.0 / 2 516 457 (71) Applicant: Regeneron Pharmaceuticals, Inc. Tarrytown, NY 10591‑6707 (US) (72) Inventors: • MACDONALD, Lynn White Plains (US) • TU, Naxin Pleasantville (US) • GURER, Cagan Valhalla (US) • STEVENS, Sean San Francisco (US) • MURPHY, Andrew, J. Croton-on-Hudson (US) (74) Representative: J A Kemp LLP 80 Turnmill Street London EC1M 5QU (GB) Remarks: •The complete document including Reference Table(s) and the Sequence Listing(s) can be downloaded from the EPO website •This application was filed on 18‑12‑2025 as a divisional application to the application mentioned under INID code 62. (54) LOW AFFINITY FC GAMMA R DEFICIENT MICE (57) Genetically modified non-human animals and methods and compositions for making and using them areprovided,wherein thegeneticmodificationcomprises a deletion of the endogenous low affinity FcyR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcyR genes from the endogenous FcyR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. EP 4 70 6 38 8 A 2 Processed by Luminess, 75001 PARIS (FR) Description FIELD OF INVENTION
[0001] The field of invention is genetically modified non-human animals that lack endogenous murine FcγR genes, including genetically modified animals that comprise a replacement of endogenous FcγR genes with human FcγRgenes, and includingmice that are capable of expressing at least two, three, four, or five functional human lowaffinity FcγRgenes, and including geneticallymodifiedmice comprising immunecells that donot express endogenous lowaffinity FcγRgenes. BACKGROUND
[0002] Fc receptors (FcRs) are proteins found on the surface of cells of the immune system that carry out a variety of functions of the immune system inmammals. FcRs exist in a variety of types, on a variety of cells, andmediate a variety of immune functions such as, for example, binding to antibodies that are attached to infected cells or invading pathogens, stimulating phagocytic or cytotoxic cells to destroy microbes, or infected cells by antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity (ADCC).
[0003] ADCC is a process whereby effector cells of the immune system lyse a target cell bound by antibodies. This process depends on prior exposure to a foreign antigen or cell, resulting in an antibody response. ADCC can bemediated through effector cells such as, for example, natural killer (NK) cells, by binding of FcR expressed on the surface of the effector cell to the Fc portion of the antibody which itself is bound to the foreign antigen or cell. Because of the central role that FcRs play in the immune response, useful non-human animals that co-express multiple human FcRs are needed, includingnon-humananimals that co-expressmultiplehuman lowaffinityFcRs.Thereexistsaneed for non-humananimal modelsof humanFcR functionandhumanprocessesofADCCfor thestudyandelucidationofhumandisease therapies, in particular anti-tumor therapies and therapies for treatingautoimmunediseases, andpharmaceutical drugdevelopment, in particular in the development, design, and testing of human antibody pharmaceuticals. BRIEF DESCRIPTION OF THE FIGURES
[0004] Figure1 isa schematic depictionof awild type lowaffinityFcγR locus in amouse, showingmouseFcγRIIB,FcγRIVand FcγRIII genes and a mouse FcγR targeting vector used for a targeted deletion of these genes, which includes a neomycin cassette flanked by site-specific recombination sites. Figure 2 shows histograms of splenocytes gated for B cells (anti-CD19), NK cells (anti-NKp46) and macrophages (anti-F4 / 80) including expression of endogenous mFcγRII and mFcγRIII genes for wild type and low affinity FcγR α- chain gene-deficient mice (mFcγR KO). . Figures 3A‑3D show in vivo depletion of B cells with a human anti-humanCD20 antibody with mouse Fc (Ab 168) or human Fc (Ab 735) in humanized CD20 mice (hCD20) and humanized CD20 mice bred to FcyR knockout mice (hCD20 / FcγR KO) in several lymphocyte compartments: bone marrow (Figure 3A), blood (Figure 3B), lymph node (Figure 3C) and spleen (Figure 3D). For each graph, the y-axis shows the percent of gated B cells (B220+ / IgM+ or B220+ / CD19+) and the x-axis shows theantibody dose for eachanimal group: 10mg / kgControl antibody (C), 2mg / kg human anti-human CD20 antibody (2 Ab) and 10 mg / kg human anti-human CD20 antibody (10 Ab). Figure 4 is a schematic depiction of a neomycin-targeted deletion of the low-affinity mouse FcγR locus and a second targeting vector for inserting two human low affinity FcγR genes (hFcγRIIIA and hFcγRIIA) into the deleted mouse locus, which includes a hygromycin cassette flanked by site-specific recombination sites. For expression of hFcγRIIA on platelets, an extended promoter region operably linked to the hFcγRIIA gene of the Human FcγRIIIA-IIATargeting Vector is employed; to prevent expression of hFcγRIIA on platelets, the promoter region is omitted or substantially omitted. Figure 5A shows histograms of splenocytes gated for NK cells (anti-NKp46) andmacrophages (anti-F4 / 80) including expressionof humanFcγRIIIA forwild typeandhumanFcγRIIIA-IIAhomozygotemice (HumanFcγRIIIA / FcγRIIAHO). Figure 5B shows histograms of splenocytes gated for neutrophils (anti-Ly6G) and macrophages (anti-F4 / 80) including expression of human FcγRIIA for wild type and human FcγRIIIA-IIA homozygotemice (HumanFcγRIIIA / Fc- γRIIA HO). Figure 6 is a schematic depiction of a hygromycin-targeted deletion of the low affinity mouse FcγR locus including an insertion of two lowaffinity humanFcγRgenes (hFcγRIIIAandhFcγRIIA) anda third targeting vector for inserting three additional low affinity human FcγR genes (hFcγRIIB, hFcγRIIIB and hFcγRIIC) and a neomycin cassette flanked by site-specific recombination sites. Figure 7 shows histograms of splenocytes gated for B cells (anti-CD19) and neutrophils (anti-Ly6G) including 2 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 expressionof humanFcγRIIBandhumanFcγRIIIB forwild typeandhumanFcγRIIIA-IIIB-IIA-IIB-IIChomozygotemice (Human FcγRIIIA / FcγRIIIB / FcγRIIA / FcγRIIB / FcγRIIC HO). SUMMARY
[0005] Geneticallymodified cells, non-humanembryos, non-humananimals andmethodsand compositions formaking and using them are provided. In various aspects, the non-human animals comprise a human FcγR receptor, a deletion of an endogenous low affinity FcγR receptor, and / or a replacement of an endogenous FcγR receptor with a human FcγR receptor at an endogenous mouse low affinity FcγR locus.
[0006] In one aspect, genetically modified cells, non-human embryos, and non-human animals are provided that comprise a functional FcR γ-chain, wherein the cells, embryos, and animals comprise a further modification comprising a replacement of the lowaffinityendogenousnon-humanFcγRgenesequences (e.g., FcγRIIB,FcγRIVandFcγRIII)withone ormore lowaffinity humanFcγRgenesequences (e.g., selected fromFcγRIIA,FcγRIIB,FcγRIIC,FcγRIIIA,FcγRIIIB, anda combination thereof).
[0007] In oneembodiment, thecells, non-humanembryos, andnon-humananimals aremurine. Inoneembodiment, the functional FcR γ-chain is amouseFcR γ-chain. In one embodiment, themouseFcR γ-chain is anFcR γ-chain endogenous to the mouse, the cell, or the embryo.
[0008] In one embodiment, the cells, embryos, and animals are mice, and the mice express a functional α-chain of a human low affinity FcγR receptor and a functional endogenous mouse γ-chain.
[0009] In one aspect, a geneticallymodifiedmouse is provided,wherein themousedoes not express an endogenousα- chain selected from an FcγRIIB α-chain, an FcγRIV α-chain, an FcγRIII α-chain, and a combination thereof; wherein the mouse expresses a functional endogenous mouse γ-chain.
[0010] In a specific embodiment, the mouse does not express a functional FcγRIIB α-chain, does not express a functional FcγRIV α-chain, and does not express a functional FcγRIII α-chain.
[0011] In oneembodiment, themousegenomecomprisesadeletionof anendogenousFcγRIIBα-chain, adeletionof an endogenous FcγRIV α-chain, and a deletion of an endogenous FcγRIII α-chain.
[0012] In one embodiment, the mouse comprises a deletion of an endogenous FcγRIIB α-chain, a deletion of an endogenous FcγRIVα-chain, and a deletion of an endogenous FcγRIIIα-chain, and further comprises a reduced ability to make an immune response to an antigen as comparedwith awild typemouse’s ability with respect to the sameantigen. In one embodiment, the reduced immune response includes a decreased antibody-dependent cell-mediated cytotoxicity (ADCC). In one embodiment, the reduced immune response includes a reduced ability in a cell killing assay to achieve antibody-dependent NK cell killing. In specific embodiments, the reduction in ADCCor antibody-dependent NK cell killing is at least 50%, in one embodiment at least 75%, in one embodiment at least 90%.
[0013] In one embodiment, the mouse comprises a deletion of an endogenous FcγRIIB α-chain, a deletion of an endogenous FcγRIV α-chain, and a deletion of an endogenous FcγRIII α-chain, and further comprises an increased humoral antibody response upon immunization with an antigen as compared to a wild type mouse, e.g., a mouse of the sameorsimilar strain that doesnot comprise thedeletion. Inoneembodiment, the increasedhumoral antibody response is 2-fold as compared to a wild type mouse. In one embodiment, the increased humoral antibody response is 3-fold as compared to a wild typemouse. In one embodiment, the increased humoral antibody response is 5-fold as compared to a wild type mouse. In one embodiment, the increased humoral antibody response is 7-fold as compared to a wild type mouse. In one embodiment, the increased humoral antibody response is 10-fold as compared to a wild type mouse. In a specific embodiment, humoral antibody response is measured by micrograms of antibody that specifically binds an antigen (withwhich themousehasbeen immunized) permicrogramof serumprotein from themouse. In oneembodiment, the increased humoral antibody response is with respect to an antigen to which awild typemouse exhibits tolerance, or to an antigenwhich in awild typemouse exhibits a poor orminimal humoral immune response. In a specific embodiment, the antigen is amouseantigen. In a specific embodiment, the antigen is a humanantigen that exhibits an identitywith amouse protein of at least about 95%, 96%, 97%, 98%, or 99%.
[0014] In one aspect, a genetically modifiedmouse is provided, comprising a replacement of a low affinity mouse FcγR α-chain genewith a low affinity human FcγRα-chain gene, wherein the replacement is at the endogenousmouse FcγRα- chain gene locus. In one embodiment, the low affinity mouse FcγR α-chain gene is selected from an FcγRIIB, FcγRIVand an FcγRIII α-chain gene. In a specific embodiment, a genetically modified mouse is provided, wherein the mouse expresses an endogenous FcR γ-chain, and wherein the low affinity human FcγR α-chain gene is FcγRIIIA α-chain. In another specific embodiment, the genetically modified mouse expresses an endogenous FcR γ-chain and a functional humanFcγRIIIAα-chainonNKcells. In a specific embodiment, the functionality of FcγRIIIAα-chainonNKcells is reflected by human antibody-mediated NK killing (e.g., ADCC mediated by a human antibody).
[0015] In one aspect, a genetically modified cell, non-human embryo, or non-human animal is provided, wherein the genetic modification comprises a replacement of at least one endogenous low affinity FcγR α-chain gene with a human FcγRα-chain gene, and the cell, embryo, or animal expresses a functional FcR γ-chain. In one embodiment, the functional 3 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 FcRγ-chain is an endogenousFcR γ-chain. In one embodiment, the lowaffinity humanFcγRα-chain gene is selected from an FcγRIIA α-chain gene, an FcγRIIIA α-chain gene, and a combination thereof. In a specific embodiment, the human FcγRIIA gene comprises a polymorphism, wherein the polymorphism is selected from a 131His low responder poly- morphismanda131Arghigh responder polymorphism. In aspecific embodiment, theFcγRIIApolymorphism is the131His low responder polymorphism. In one embodiment, the FcγRIIIA gene is a specific allelic variant, wherein the allelic variant is selected from a 158Val variant and a 158Phe variant. In a specific embodiment, the FcγRIIIA allelic variant is the 158Val variant.
[0016] Inoneembodiment the lowaffinityhumanFcγRgene isselected fromanFcγRIIB,FcγRIIC,anFcγRIIIBgene,and a combination thereof. In a specific embodiment, the human FcγRIIB gene comprises an amino acid substitution, wherein the substitution is selected from an 232Ile or a 232Thr substitution. In another specific embodiment, amino acid substitution is a 232Ile substitution. In a specific embodiment, the FcγRIIIB gene is a specific allelic variant, wherein the allelic variant is selected from a NA1 variant and a NA2 variant. In another specific embodiment, the FcγRIIIB allelic variant is a NA2 variant.
[0017] In one embodiment the low-affinity human FcγR α-chain gene is selected from a FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, FcγRIIIB α-chain gene, and a combination thereof.
[0018] Inoneembodiment, the lowaffinitymouseFcγRIVα-chaingeneand theFcγRIIIα-chaingeneare replacedwithat least one low affinity human FcγR α-chain gene. In one embodiment, the low affinity mouse FcγRIV α-chain gene and the FcγRIIB α-chain gene are replaced with at least one low affinity human FcγR α-chain gene. In one embodiment, the low affinitymouseFcγRIIBα-chain geneand theFcγRIIIα-chain geneare replacedwithat least one lowaffinity humanFcγRα- chain gene. In a specific embodiment, the at least one low affinity human FcγR α-chain gene is selected from an FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA , FcγRIIIB α-chain gene, and a combination thereof. In another specific embodiment, the at least one lowaffinity humanFcγRα-chain gene is selected fromanFcγRIIAα-chain gene, anFcγRIIIAα-chain gene, anda combination thereof. In another specific embodiment, the at least one low affinity human FcγR α-chain gene is selected from an FcγRIIB, FcγRIIC, FcγRIIIB α-chain gene, and a combination thereof. In another specific embodiment, the low affinity mouse FcγR genes are replaced with a human FcγRIIA α-chain gene and a human FcγRIIIA α-chain gene. In another specific embodiment, the low affinity human FcγRIIA and FcγRIIIA α-chain genes comprise variants, wherein the FcγRIIA α-chain gene comprises a 131His variant and the FcγRIIIA α-chain gene comprises a 158Val variant. In another specific embodiment, the lowaffinitymouseFcγRα-chain genesare replacedwith the following lowaffinity humanFcγRα- chain genes:FcγRIIB, FcγRIICandFcγRIIIB. In another specificembodiment, the lowaffinity humanFcγRIIBα-chaingene and FcγRIIIB α-chain gene comprise variants, wherein the FcγRIIB α-chain gene comprises a 232Ile variant and the FcγRIIIB α-chain gene comprises an NA2 variant.
[0019] In oneembodiment, thegeneticmodifications comprisea replacement of syntenic genomic sequencesofmouse and human chromosome 1. In a specific embodiment, the genetic modifications comprise a replacement of a genomic fragment comprising endogenous low affinity mouse FcγR genes with a genomic fragment comprising low affinity human FcγR genes. In another specific embodiment, the mouse genome from chromosome 1:172,889,983 to chromo- some1:172,989,911 is replaced with a human genomic fragment comprising human chromosome 1:161,474,729 to chromosome1:161,620,458.
[0020] In one aspect, a genetically modified cell, non-human embryo, or non-human animal is provided, wherein the genetic modification comprises a knockout of one or more endogenous low affinity receptor α-chain genes, and the presence of an episome comprising one or more human FcγR α-chain genes. In a specific embodiment, the cell, embryo, or animal expresses a functional FcR γ-chain. In a specific embodiment, the episome is a mini chromosome. In one embodiment, the functional FcR γ-chain is endogenous to the cell, embryo, or animal.
[0021] In one aspect, a genetically modifiedmouse is provided, comprising a replacement of a low affinity mouse FcγR α-chain gene with a low affinity human FcγR α-chain gene, the mouse comprises a mouse FcRγ-chain gene, and the mouse expresses a functional human low affinity FcγR receptor. In one embodiment, the functional low affinity FcγR receptor is expressed on a cell type in which the low affinity FcγR receptor is expressed in humans. In a specific embodiment, the functional human low affinity FcγR receptor is FcγRIIIA and the FcγRIIIA is expressed on NK cells.
[0022] In one embodiment, themouse comprises a deletion of twomouseFcγRα-chain genes. In another embodiment, the mouse comprises a deletion of three mouse FcγR α-chain genes.
[0023] In one embodiment, the mouse comprises a replacement of three mouse FcγR α-chain genes with at least one human FcγR α-chain gene. In another embodiment, the mouse comprises a replacement of two mouse FcγR α-chain geneswith at least one humanFcγRα-chain gene. In a specific embodiment, themouse comprises a replacement of three mouseFcγRα-chaingeneswithat least twohumanFcγRα-chaingenes. Inanother specificembodiment, the threemouse FcγR α-chain genes are replaced with three human FcγR α-chain genes. In another specific embodiment, the mouse comprises a replacement of two mouse FcγR α-chain genes with at least two human FcγR α-chain genes. In yet another specific embodiment, the two mouse FcγR α-chain genes are replaced with at least three human FcγR α-chain genes.
[0024] In one embodiment, the low affinity mouse FcγR α-chain gene is selected from an FcγRIIB, FcγRIV, FcγRIII α- chain gene, and a combination thereof. 4 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55
[0025] In one embodiment, the low affinity human FcγR α-chain gene is selected from an FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA,FcγRIIIBα-chaingene,andacombination thereof. Inoneembodiment, the lowaffinityhumanFcγRα-chaingene is selected from an FcγRIIA, an FcγRIIIA α-chain gene, and a combination thereof. In one embodiment, the low affinity human FcγR α-chain gene is selected from an FcγRIIB, FcγRIIC, an FcγRIIIB α-chain gene, and a combination thereof.
[0026] Inoneembodiment, the lowaffinitymouseFcγRIVα-chaingeneand theFcγRIIIα-chaingeneare replacedwithat least one human FcγRα-chain gene. In one embodiment, the low-affinity mouse FcγRIVα-chain gene and the FcγRIIBα- chain geneare replacedwithat least onehumanFcγRα-chaingene. In oneembodiment, the lowaffinitymouseFcγRIIBα- chain gene and the FcγRIIIB α-chain gene are replaced with at least one human FcγR α-chain gene. In a specific embodiment, the at least onehumanFcγRα-chain gene is selected fromanFcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, FcγRIIIB α-chain gene, and a combination thereof. In another specific embodiment, the at least one human FcγR α-chain gene is selected from an FcγRIIA, an FcγRIIIA α-chain gene, and a combination thereof. In another specific embodiment, the at least one human FcγR α-chain gene is selected from an FcγRIIB, FcγRIIC, FcγRIIIB α-chain gene, and a combination thereof. In another specific embodiment, the mouse α-chain genes are replaced with the following human FcγR α-chain genes: FcγRIIA and FcγRIIIA. In yet another specific embodiment, the mouse α-chain genes are replaced with the following human FcγR α-chain genes: FcγRIIB, FcγRIIC and FcγRIIIB.
[0027] In one aspect, a genetically modified mouse is provided, comprising a low affinity human FcγR α-chain and a mouseFcR γ-chainsubunit,wherein themouseexpresses thehumanFcγRα-chainonacell selected fromaneutrophil, an eosinophil, a basophil, amonocyte, amacrophage, aplatelet, a Langerhanscell, a dendritic cell, anNKcell, amast cell, aB cell, a T cell, and a combination thereof. In one embodiment, the mouse expresses a human FcγRIIA α-chain on a cell selected froma neturophil, amacrophage, an eosinophil, a platelet, a dendritic cell, a Langerhans cell, and a combination thereof. In one embodiment, the mouse is capable of phagocytosis, ADCC and cellular activation initiated or mediated through the expressed human FcγRIIAα-chain. In one embodiment themouse expresses a human FcγRIIIAα-chain on a cell selected from amacrophage, anNK cell, amonocyte, amast cell, an eosinophil, a dendritic cell, a Langerhans cell, at least one Tcell type, and a combination thereof. In one embodiment, themouse is capable of ADCCmediated through the humanFcγRIIIAα-chain expressed onNK cells. In a specific embodiment, themouse exhibits hFcγRIIIA-mediatedADCC in response to an antibody comprising a human Fc.
[0028] In one embodiment, themouse expresses both a human FcγRIIA α-chain and a human FcγRIIIAα-chain. In one embodiment, the human FcγRIIA α-chain is expressed on platelets and the human FcγRIIIA α-chain is expressed on NK cells. In one embodiment, the mouse is capable of ADCCmediated by an antibody comprising a human Fc, wherein the mediation is througheither thehumanFcγRIIAα-chainor through thehumanFcγRIIIAα-chainexpressedon thesurfaceof accessory cells. In one embodiment, the human FcγRIIA α-chain is not expressed on platelets. In a specific embodiment wherein the human FcγRIIA α-chain is not expressed on platelets, the mouse lacks or substantially lacks a human promoter sequence that operably linked to the human FcγRIIA α-chain in a human genome.
[0029] In oneembodiment, themouseexpresses ahumanFcγRIIBα-chain onacell selected fromaBcell, amast cell, a basophil, a macrophage, an eosinophil, a neutrophil, a dendritic cell, a Langerhans cell, and a combination thereof. In a specific embodiment, the mouse expresses a human FcγRIIB α-chain on a B cell and a mast cell. In another specific embodiment, themouse is capableof endocytosis of immunecomplexesmediated through theexpressedhumanFcγRIIB α-chain. In one embodiment, the mouse expresses a human FcγRIIC α-chain on a cell selected from a neutrophil, a macrophage, an eosinophil, a platelet, a dendritic cell, a Langerhans cell, and a combination thereof. In a specific embodiment, themouse is capable of phagocytosis, ADCC and cellular activation initiated through the expressed human FcγRIIC α-chain.
[0030] In oneembodiment, themouseexpressesahumanFcγRIIIBα-chainonneutrophils andeosinophils. In a specific embodiment, themouse is capable of cellular activation, phagocytosis, ADCC and degranulation, wherein the activation, phagocytosis, ADCC, and degranulation are mediated through the expressed human FcγRIIIB α-chain.
[0031] In one aspect, a mouse is provided that comprises a deletion of the endogenous FcγRIIB, FcγRIV and FcγRIII genes and insertion of human FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB genes, and wherein the mouse comprises a functional mouse FcR γ-chain gene.
[0032] In one embodiment, the mouse comprises a deletion of the α-chains encoded by endogenous FcγRIIB, FcγRIV and FcγRIII genes and insertion of the α-chains encoded by human FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB genes.
[0033] In one embodiment, the insertion of the humanFcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, andFcγRIIIBα-chain genes is at a random location within the mouse genome.
[0034] In one embodiment, the insertion of the humanFcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, andFcγRIIIBα-chain genes is at the endogenous mouse low affinity FcγR α-chain locus.
[0035] In one embodiment, the mouse expresses human FcγRIIIA on NK cells and macrophages. In a specific embodiment, all or substantially all NK cells from a splenocyte sample of the mouse express human FcγRIIIA. In a specific embodiment, all or substantially all macrophages from a splenocyte sample of the mouse express human FcγRIIIA. 5 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55
[0036] In one embodiment, themouse expresses a human FcγR selected from human FcγRIIA, human FcγRIIIA, and a combination thereof, on a cell type selected from neutrophils, macrophages, and a combination thereof. In a specific embodiment, the mouse expresses human FcγRIIA and human FcγRIIIA on all or substantially all neutrophils and macrophages of a splenocyte sample from the mouse.
[0037] In one embodiment, the mouse expresses human FcγRIIB and human FcγRIIIB on B cells and neutrophils of B cells fromaBcell-gated splenocyte sample from themouse. In a specific embodiment, themouseexpressesFcγRIIIB and FcγRIIB on all or substantially all B cells and neutrophils from a B cell-gated splenocyte sample from the mouse.
[0038] In one embodiment, themouse further comprises a humanizedCD20 gene. In one embodiment, themouse that further comprises the humanized CD20 gene following treatment with an anti-CD20 binding protein that comprises an Fc exhibits depletion (in vivo) of B cells. In one embodiment, the depletion is in a compartment selected from bone marrow, blood, lymph node, spleen, and a combination thereof. In one embodiment, the Fc is a human Fc. In one embodiment, the Fc is a mouse Fc. In one embodiment, the anti-CD20 binding protein is an anti-CD20 antibody.
[0039] In one aspect, a cell is provided comprising a genetic modification as described herein. In one embodiment, the cell is selected froman embryonic stem (ES) cell, a pluripotent cell, an induced pluripotent cell, and a totipotent cell. In one embodiment, the cell is selected from amouse cell and a rat cell. In a specific embodiment, the cell is an ES cell. In amore specific embodiment, the cell is a mouse ES cell.
[0040] In one aspect, a non-human embryo is provided, comprising a genetic modification as described herein. In one embodiment, the non-human embryo is selected from a mouse embryo and a rat embryo.
[0041] In one aspect, amethod is provided for determining efficacy of a therapeutic. In one embodiment, the therapeutic is an antibody (e.g., mono‑, bi‑, tri‑, multispecific) comprising a human Fc. In one embodiment, the therapeutic is a human antibody. In one embodiment, the efficacy is efficacy of therapeutic-mediated cell killing (e.g., ADCC). In a specific embodiment, the human therapeutic is a fusion protein comprising an Fc of a human immunoglobulin heavy chain. In one embodiment, the therapeutic is administered to amouse as described herein and a level of therapeutic-dependent ADCC is measured. In one embodiment, the mouse is used to assess the ADCC activity of a therapeutic by administering the therapeutic to themouse and then detecting (e.g., in vitro from a sample (e.g., blood) taken from the animal) binding of the therapeutic to a human low affinity FcγR on an FcγR-expressing cell. In a specific embodiment, accessory cells of the mouse are isolated from the mouse and tested for the ability, in the presence and absence of the therapeutic, to mediate therapeutic-dependent ADCC.
[0042] In one aspect, a method is provided for determining whether a low affinity FcγR is associated with a human disease or disorder, comprising a step of determining a trait associated with the human disease or disorder in a mouse according to the invention. In one embodiment, the trait is a phenotype associatedwith the absence or loss of a function of oneormore lowaffinityFcγRs. Inaspecificembodiment, thediseaseordisorder isanautoimmunediseaseordisorder. Ina specific embodiment, the autoimmune disease or disorder is selected from Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), type I diabetes, Guillain-Barré syndrome, sclerosis, multiple sclerosis, Goodpasture’s syndrome, Wegener’s Granulomatosis and experimental autoimmune encephalomyelitis (EAE). In a specific embodiment, the mousecomprisesapolymorphism ina lowaffinityFcγR,and the trait is selected fromanenhancedability tomediateADCC in comparison to the majority of the human population that does not bear the polymorphism, and a reduced ability to mediate ADCC in comparison to the majority of the human population that does not bear the polymorphism.
[0043] In one aspect, a method for making an anti-human FcR α-chain antibody in a mouse is provided, comprising exposing a mouse according to the invention to a human FcR as described herein. In one embodiment, an antibody that recognizes thehumanFcR is isolated from themouse. Inanother embodiment, anucleic acid sequence that encodesall or part of a variable region of an antibody that recognizes the human FcR is identified and cloned.
[0044] In one aspect, a method for determining ability of anti-human FcR antibodies to target molecules to FcR- expressing cells for phagocytosis of the targetmolecule is provided, comprising exposing amouse as described herein to an agent comprising an anti-human FcR antibody, and measuring phagocytosis of the target molecule.
[0045] In one aspect, amethod is provided formaking an antibody, in amouse, to an antigen that is poorly immunogenic in amouse that iswild typewith respect to oneormoreFcγRs, comprisingexposingamouseasdescribedherein that lacks amouse low affinity FcR but expresses an FcγR γ-chain to the antigen that is poorly immunogenic in themouse that is wild type with respect to one or more FcγRs, and identifying an antibody that recognizes the poorly antigenic antigen. In one embodiment, the method comprises isolating the antibody from the mouse. In another embodiment, a nucleic acid sequence that encodes all or part of a variable region of the antibody is identified and cloned.
[0046] In one aspect, amethod formaking amouse capable ofmaking antibodies comprising human variable regions is provided, comprising a step of breeding a first mouse as described herein with a secondmouse that comprises (a) one or morehuman immunoglobulin variable regiongenesegmentsandoneormorehumanconstant regiongenes; or, (b) oneor more human immunoglobulin variable region gene segments operably linked to a mouse constant region gene, wherein the human gene segments replace variable region gene segments at the mouse variable region gene segment locus.
[0047] In one embodiment, the second mouse (a) comprises a transgene that comprises one or more human immunoglobulin light chain variable region gene segments and a human light chain constant gene, and a transgene 6 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 that comprises one or more human immunoglobulin heavy chain variable region gene segments and one or more human heavy chain constant genes. In one embodiment, the transgene that comprises one or more human immunoglobulin heavy chain variable region gene segments comprises two or more heavy chain constant genes and is capable of class switching. In a specific embodiment, the mouse comprises an inactivated endogenous light chain locus and / or an inactivated endogenous heavy chain locus. In a specific embodiment, themouse comprises a deletion of an endogenous light chain locus and / or a deletion of an endogenous heavy chain locus.
[0048] In one embodiment, the second mouse (b) comprises human heavy and human light variable region gene segments, at the heavy an light mouse loci, respectively.
[0049] In one aspect, a method is provided for selecting an anti-tumor antibody, comprising a step of determining the ability of anantibody tomediateADCC,wherein theability of theantibody tomediateADCC is testedbydeterminingADCC mediated by a cell of a mouse as described herein, and the antibody is selected if it mediates ADCC employing a cell of a genetically modified mouse as described herein. In a specific embodiment, binding of the antibody to the cell of the geneticallymodifiedmouse isdetermined,and theanti-tumorantibody is selected for itsability tobindahumanFcγRon the cell. In a specific embodiment, the human FcγR is a low affinity FcγR.
[0050] In oneembodiment, the anti-tumor antibody is identifiedby its enhancedability tomediateADCC throughacell of the mouse as compared to ability of the anti-tumor antibody to mediate ADCC through a cell of a wild type mouse. In a specific embodiment, the anti-tumor antibody is identified by its ability to mediate ADCC through NK cells. In a specific embodiment, the NK cells express human FcγRIIIA.
[0051] In oneembodiment, amethod is provided for selectingananti-tumoragent, comprisingastepof administeringan agent comprising a human Fc or a modified human Fc to a first non-human animal wherein the first non-human animal is geneticallymodified in accordancewith the invention and comprises a human tumor; a step of administering the agent to a secondnon-humananimal comprising the tumor; anddetermining theability of the first non-humananimal and the second non-humananimal to retardgrowthof thehuman tumor followingadministrationof theagent,wherein theagent is selected as an anti-tumor agent if it exhibits an enhanced ability to retard growth of the human tumor in the first non-human animal but not in the second non-human animal.
[0052] In one embodiment, the first non-human animal is modified to comprise a deletion of an endogenous FcR α- subunit, and ismodified tocompriseahumanFcRα-subunit selected from thegroupconsistingofanFcγRIIAα-subunit, an FcγRIIBα-subunit, an FcγRIICα-subunit, an FcγRIIIAα-subunit, an FcγRIIIBα-subunit, and a combination thereof. In one embodiment, the second animal is a wild type animal. In one embodiment, the first non-human animal expresses an endogenous FcR γ-chain.
[0053] In one embodiment, the first non-human animal expresses a functional endogenous FcγRI.
[0054] In one aspect, a method is provided for making a mouse that lacks a low affinity mouse FcγR, expresses a functional FcR γ-chain, and comprises genes encoding α-chains of the human FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB, comprising a step of replacing the low affinity mouse FcγR α-chains with human FcγR α-chains, at the mouse FcγR α-chain locus.
[0055] In one embodiment, a first step comprises deleting the α-chains of the endogenous FcγRIIB, FcγRIVand FcγRIII genes and inserting the α-chains of the human FcγRIIA and FcγRIIIA genes; a second step comprises inserting the α- chains of the human FcγRIIB, FcγRIIC and FcγRIIIB genes into themouse genome that results from the first step; wherein themouse comprises a functionalmouseFcR γ-chain gene. In a specific embodiment, theα-chains of the humanFcγRIIB, FcγRIIC and FcγRIIIB genes of the second step are inserted 5’ relative to the α-chains of the human FcγRIIA and FcγRIIIA genes of the first step.
[0056] In one aspect, a method for determining cell killing by a human therapeutic in a non-primate is provided, comprising a step of exposing a cell, non-human embryo, or non-human animal to a human therapeutic that comprises a human Fc, wherein the cell, embryo, or animal comprises a functional FcR γ-chain and comprises a replacement of one or more endogenous low affinity FcγR α-chain genes with one or more human FcγR α-chains, and determining the ability of the human therapeutic to mediate cell killing through a low affinity human FcγR of the cell, embryo, or animal.
[0057] In one embodiment, the non-primate is a mouse. In a specific embodiment, endogenous mouse FcγR α-chain genes FcγRIIB, FcγRIV and FcγRIII are replaced with human FcγR α-chain genes FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB.
[0058] In one embodiment, the cell is selected from a B cell, a mast cell, a basophil, a macrophage, an eosinophil, a neutrophil, a dendritic cell, a Langerhans cell, and a combination thereof. In a specific embodiment, the cell is an NK cell andNKcell-mediatedADCCbyahumanor a humanizedantibody is determined. In a specific embodiment, the lowaffinity human FcγR is a human FcγRIIIA.
[0059] In one aspect, a method for determining therapeutic-dependent thrombosis is provided, comprising exposing a first non-human animal that expresses a human FcγRIIA on a platelet to a therapeutic; exposing a second non-human animal that does not express the humanFcγRIIA ona platelet to said therapeutic;measuring in the first non-humananimal and in the second non-human animal an amount of therapeutic-dependent thrombosis; and, determining a difference in therapeutic-dependent thrombosis. 7 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55
[0060] In one embodiment, the non-human animal is selected from a mouse and a rat.
[0061] In oneembodiment, thedetermineddifference in therapeutic-dependent thrombosis is employed to identify a risk associated with administering the therapeutic to a human. In one embodiment, the determined difference results in a change of administration of the therapeutic to a human patient in need thereof. DETAILED DESCRIPTION
[0062] The invention is not limited to particular methods, and experimental conditions described, as suchmethods and conditionsmay vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the claims.
[0063] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art towhich this invention belongs. Although anymethods andmaterials similar or equivalent to those described herein can be used in the practice or testing of the present invention, particular methods andmaterials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.
[0064] The phrase "targeting construct" includes a polynucleotide molecule that comprises a targeting region. A targeting region comprises a sequence that is substantially homologous to a sequence in a target cell, tissue or animal and provides for integration of the targeting construct into a position within the genome of the cell, tissue or animal. In a specific embodiment, the targeting construct further comprises a nucleic acid sequence or gene of particular interest, a selectable marker, control and or regulatory sequences, and other nucleic acid sequences that allow for recombination mediated through the exogenous addition of proteins that aid in or facilitate recombination involving such sequences. In another specific embodiment, the targeting construct further comprises agene of interest, wherein the gene of interest is a heterologous gene that encodes a protein that has a similar function as a protein encoded by the endogenous sequence.
[0065] The term "replacement" includes wherein a DNA sequence is placed into a genome of a cell in such a way as to replace a sequencewithin a genome, at the locus of the genomic sequence, with a heterologous sequence (e.g., a human sequence in a mouse), unless otherwise indicated. The DNA sequence so placed may include one or more regulatory sequences that are part of source DNA used to obtain the sequence so placed (e.g., promoters, enhancers, 5’‑ or 3’- untranslated regions, etc.). For example, in various embodiments, the replacement is a substitution of an endogenous sequence for a heterologous sequence that results in the production of a gene product from theDNA sequence so placed (comprising the heterologous sequence), but not expression of the endogenous sequence; the replacement is of an endogenous genomic sequence with a DNA sequence that encodes a protein that has a similar function as a protein encoded by the endogenous genomic sequence (e.g., the endogenous genomic sequence encodes a low affinity mouse FcγR receptor, and the DNA fragment encodes one or more human low affinity FcγR receptors, such as, e.g., a human FcγRIIC and / or an FcγRIIIB).
[0066] The term "FcγR" includes a receptor for an Fc, e.g., an Fc portion of an IgG immunoglobulin. The FcγR genes include anα-chain that is expressed on the surface of the cell and serves as a ligand-binding domain, and associates with eitherahomodimerof theFcR γ-chainoraheterodimerof theFcR γ-chainand theδ-chain.Thereareseveral differentFcγR genesand theycanbecategorized into lowaffinityandhighaffinity typesaccording topreferential binding to IgG in immune complexes. Lowaffinity FcyRgenes in humans include FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB andwithinmost of these genes naturally occurring genetic differences, or polymorphisms, have been described in human subjects with autoimmune diseases. Persons of skill upon reading this disclosure will recognize that one or more endogenous low affinity FcγRgenes in a genome (or all) canbe replacedbyoneormoreheterologous lowaffinityFcγRgenes (e.g., variants or polymorphisms such as allelic forms, genes from another species, chimeric forms, etc.).
[0067] The phrase "allelic variants" includes variations of a normal sequence of a gene resulting in a series of different forms of the same gene. The different forms may comprise differences of up to, e.g., 20 amino acids in the sequence of a protein from a gene. For example, alleles can be understood to be alternative DNA sequences at the same physical gene locus, which may or may not result in different traits (e.g., heritable phenotypic characteristics) such as susceptibility to certain diseases or conditions that do not result in other alleles for the same gene or result in varying degrees in the other alleles.
[0068] An "accessory cell" includes an immune cell that is involved in the effector functions of the immune response. Exemplary immune cells include a cell of lymphoid or myeloid origin, e.g., lymphocytes, natural killer (NK) cells, monocytes, macrophages, neutrophils, eosinophils, basophils, platelets, Langerhans cells, dendritic cells, mast cells etc. Accessory cells carry out specific functions of the immune system through receptors, e.g., FcRs, expressed on their surfaces. In a specific embodiment, an accessory cell is capable of triggering ADCCmediated through an FcR, e.g., a low affinity FcγR, expressed on the cell surface. For example, macrophages expressing FcRs are involved in phagocytosis and destruction of antibody-coated bacteria. Accessory cells might also be capable of releasing an agent that mediates other immune processes. For example, mast cells can be activated by antibody bound to FcRs to release granules, e.g., inflammatory molecules (e.g., cytokines) at a site of infection. In various other embodiments, the expression of FcRs on accessory cells can be regulated by other factors (e.g., cytokines). For example, FcγRI and FcγRIII expression can be 8 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 inducted by stimulation with interferon-γ (IFN-γ). Mouse and Human FcRs
[0069] The receptors for theFc (i.e., constant) regionsof immunoglobulins (FcRs)playan important role in the regulation of the immune response. FcRsarepresent onaccessory cells of thehost’s immunesystem toeffectively disposeof foreign antigens bound by an antibody. FcRs also play important roles in balancing both activating and inhibitory responses of the accessory cells of the immune system. FcRs are involved in phagocytosis by macrophages, degranulation of mast cells, uptake of antibody-antigen complexes and modulation of the immune response, as well as other immune system processes.
[0070] Inmice and humans, distinct FcRs are differentially expressed on the surface of different accessory cells that are each specific for the immunoglobulin isotypes present in the expressedantibody repertoire. For example, immunoglobulin G (IgG) antibodies mediate effector functions through IgG receptors (FcγRs). FcγRs have been classified into three groups: highaffinity activatingFcγRI (CD64), lowaffinity inhibitoryFcγRII (CD32) and lowaffinityactivatingFcγRIII (CD16). Although each group is present in both mice and humans, the number of isoforms and subsets of immune cells on which they are present are different. For example, FcγRIIA and FcγRIIIB are expressed on accessory cells in humans but are reportedly absent from mice. Further, affinities of the different IgG isotypes (e.g., IgG1) for each FcγR is different in mice and humans.
[0071] Activation or inhibition of cell signaling throughFcγRsand the effector functions associatedwith antibody binding toFcγRsarebelieved tobemediatedbyspecific sequencemotifs of intracellular domainsofFcγRs, orof the subunits of co- receptors. Activating receptors aremost commonly associated with the common γ-chain (FcR γ-chain) which contains an immunoreceptor tyrosine-basedactivationmotif (ITAM). ITAMscontainaspecific sequenceof about 9‑12aminoacids that include tyrosine residues that are phosphorlyated in response to antibody binding to an FcR. Phosphorylation leads to a signal transduction cascade. Mice that lack a gene encoding an FcR γ-chain (FcR γ-chain KO) have been reported (e.g., see Takai et al. (1994) FcR γChainDepletionResults in Pleiotrophic EffectorCell Defects, Cell 76:519‑529; vanVugt et al. (1996) FcR γ-Chain Is Essential for Both Surface Expression and Function of Human FcγRI (CD64) In Vivo, Blood 87(9):3593‑3599; and Park et al. (1998) Resistance of Fc Receptor-deficient Mice to Fatal Glomerulonephritis, J. Clin. Invest. 102(6):1229‑1238). TheFcR γ-chain is reportedly essential for proper surfaceexpression and function (e.g., signal transduction, phagocytosis, etc.) of most of the FcRs; FcR γ-chain KO mice lack FcγRI according to some reports. However, other reports reveal that FcR γ-chain KOmice indeed express FcγRI on the surface of certain accessory cells, and theFcγRI expressed reportedly appears functional in that it binds IgG inmice in theabsenceof expressedFcR γ-chain (Barnes et al. (2002) FcyRI-Deficient Mice ShowMultiple Alterations to Inflammatory and Immune Responses, Immunity 16:379‑389).
[0072] In contrast, FcγRIIB is an inhibitory receptor that contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. Like ITAMs, ITIMs are sequencemotifs that include phosphorylatable tyrosine residues. However, downstream events following phosphorylation of an ITM lead to inhibition, not activation, of immune cell functions. Mice deficient in FcγRIIB reportedly exhibit an increased antibody response in comparison to wild type mice (Takai et al. (1996) Augmented humoral and anaphylactic responses in FcgRII-deficient mice, Nature 379:346‑349), an observation that supports the role of FcγRIIB as a downregulator of the B cell antibody response.
[0073] In humans, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB are considered the classical low affinity FcγR genes and are located together on the same chromosome (Su et al. (2002)Genomic organization of classical human low- affinity Fcy receptor genes, Genes and Immunity 3 (Supple 1):S51-S56). These genes exhibit several polymorphisms associatedwithdistinct phenotypes,e.g., analterationof ligandbindingand functionof the receptor.Somepolymorphisms are associated with autoimmune diseases, e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Transgenic mice for different human FcγRs (hFcγRs) have been developed and used as disease models, generating high affinity antibodies, testing therapeutic antibodies for ability to elicit specific cellular responses, screening compounds that ameliorate aberrant immune responses, etc. (e.g., see Heijnen et al. (1996) A Human FcgRI / CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics, J. Hematother. 4:351‑356; HeijnenandvandeWinkel (1996)AntigenTargeting toMyeloid-specificHumanFcgRI / CD64TriggersEnhancedAntibody Responses in Transgenic, J. Clin. Invest. 97(2):331‑338; US Pat Nos. 6,111,166, 6,676,927, 7,351,875, 7,402,728, and 7,416,726).
[0074] Despite the significant roles of the FcRs in providing the bridge between antibodies and accessory cells of the immune system, nomodel system currently exists in which all the low affinity hFcγRs are expressed. Amouse in which all the low-affinity hFcγRs are co-expressed-including mice that lack endogenous mouse FcγRs-in various embodiments could be used to accurately reflect effects of a human antibody therapeutic, including ADCC-mediated effects. Such a mouse would serve as a vital tool in the engineering, analysis and evaluation of therapeutic antibodies for treatment of human diseases such as, e.g., RA, type I diabetes, SLE, and autoimmunity, by providing an animal model capable of achievingamoreaccurateassessmentof immunological processes inhumans,particularly in thecontextof testinghuman 9 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 antibody therapeutics. Themouse will also be a valuable source of cells bearing the low affinity receptors, which cells can be used in in vitro assays for assessing therapeutic-dependent cell killing for therapeutics that bind the low affinity receptors, and thus for identifying useful human therapeutics. Endogenous Low Affinity FcγR Gene Deficient Mice
[0075] Genetically modified non-human animals are provided that do not express endogenous low affinity mouse FcγR genes, but that express an endogenous mouse FcR γ-chain. In various embodiments, the FcR γ-chain is expressed in a distribution (i.e., in cell types) and at a level in themouse that is the sameor substantially the sameas in awild typemouse. Endogenous low affinity FcγRgenes can be expressed either on the surface of immune cells or in a solublemanner in the periphery of the animals. Genetic modifications for making a non-human animal that does not express endogenous low affinitymouseFcγRgenes are conveniently described by using themouse as an illustration. A geneticallymodifiedmouse according to the invention can be made in a variety of ways, particular embodiments of which are discussed herein.
[0076] A schematic illustration (not to scale) of low affinity mouse FcγR gene locus is provided in Figure 1 (top) to show FcγR gene arrangement at the endogenous locus. As illustrated, low affinity mouse FcγR genes FcγRIIB, FcγRIV and FcγRIII are present together in close proximity on one chromosome. Each of these genes comprise the α-chain or ligand binding domain responsible for the binding the Fc portion of an antibody molecule.
[0077] Ageneticallymodifiedmouse lacking a nucleotide sequence encoding anα-chain of the endogenous low affinity FcγRgenescanbemadebyanymethodknown in theart. For example, a targeting vector canbemade that deletes the low affinitymouseFcγRα-chain geneswith selectablemarker gene. Figure1 illustrates amousegenome (bottom) targetedby a targeting construct having a 5’ homology arm containing sequence upstream of the endogenous low affinity FcγR α- chain locus, followed by a drug selection cassette (e.g. a neomycin resistance gene flanked by loxP sequences), and a 3’ homology arm containing sequence downstream of the endogenous low affinity FcγR α-chain locus. Upon homologous recombination at the locus, the endogenous low affinity FcγR α-chain locus is replaced by a drug selection cassette (bottom of Figure 1). The endogenous low affinity FcγR α-chain gene locus is thereby deleted resulting in a cell or non- human animal that does not express endogenous low-affinity mouse FcγR α-chain genes. The drug selection cassette may optionally be removed by the subsequent addition of a recombinase (e.g., by Cre treatment).
[0078] Genetically modifying a mouse to render an endogenous low-affinity mouse FcγR α-chain gene or genes nonfunctional, in various embodiments, results in amouse that exhibits defects in immune responses, making themouse useful for evaluating cooperative, as well as individual, roles of the endogenous low-affinity mouse FcγR genes in normal anddisordered immune function, IgG-mediatedprocesses, andautoimmunedisease. In variousembodiments,modifying the α-chains of the endogenous low-affinity mouse FcγR genes, but not the FcR γ-chain, avoids a potential reduction of other endogenous FcR genes (e.g., high affinity FcγRI) that require the FcR γ-chain for surface expression and function, thus maintaining various other immunological functions and processes mediated through γ-chain-dependent processes.
[0079] According to some reports, FcR γ-chain deficient mice lack surface expression of FcγRIII and FcγRI. However, FcγRI has reportedly been detected on the cell surface in FcR γ-chain deficient mice and is reportedly at least partially functional. In contrast, mice according to the present invention contain unmodified endogenous FcR γ-chain, which preserves natural cell surface expression patterns and cellular functions of other FcR genes that require FcR γ-chain.
[0080] In various embodiments, mice of the present invention present an advantage over other FcγR gene-deficient mice in that the genetic modifications that they bear result in the maintenance of other genes necessary for other immunological functions not entirely devoted to low affinity FcγR genes. For example, with a functional FcR γ-chain, other γ-chain-dependent proteins (e.g., FcγRI) will be able to associate with the FcR γ-chain and participate in effector cell functions in the immune response. In various geneticallymodifiedmice in accordancewith the invention, it is believed that maintaining such functions (due to the presence of a functional FcRγ-chain) while deleting endogenous low affinity FcγR genes (one or more α-subunits) enables a more precise elucidation of the roles of FcRs in autoimmunity. Low Affinity FcγR Humanized Mice
[0081] Genetically modified non-human animals are provided that express low-affinity human FcγR genes. Low affinity humanFcγRgenescanbeexpressedeitheron thesurfaceofaccessorycellsof theanimal’s immunesystemor inasoluble manner in the periphery of the animals.
[0082] The genetic modification, in various embodiments, comprises a deletion of a functional α-chain of one or more low-affinity mouse FcγR genes, and in some embodiments a further modification comprising a replacement with two or more, with three ormore, with four or more, or with five low-affinity human FcγR α-subunit genes, wherein the non-human animal expresses a functional mouse FcR γ-chain gene. Genetically modified non-human embryos, cells, and targeting constructs for making the non-human animals, non-human embryos, and cells are also provided.
[0083] Compositions and methods for making a mouse that expresses a human FcγR gene, including specific polymorphic forms or allelic variants (e.g., single amino acid differences), are provided, including compositions and 10 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 method for making a mouse that expresses such genes from a human promoter and a human regulatory sequence. The methods includeselectively renderinganendogenous lowaffinitymouseFcγRgenenonfunctional (e.g.,byadeletionof its α-chain), and employing an α-chain of a low affinity human FcγR gene at the endogenous low affinity mouse FcγR gene locus to express a low affinity human FcγRα-subunit gene in amouse. The deletion of the low affinitymouse FcγRgene is made by deletion of one or more α-chain genes, but not an FcRγ-chain gene. The approach selectively renders one or more endogenous low affinity FcγR α-chain genes nonfunctional while retaining a functional endogenous FcRγ-chain.
[0084] The endogenous FcγR α-chain replacement approach employs a relatively minimal disruption in natural FcγR- mediated signal transduction in theanimal, in variousembodiments, because thegenomic sequenceof theFcγRα-chains are replaced in a single fragment and therefore retain normal functionality by including necessary regulatory sequences. Thus, in such embodiments, the FcγR α-chain modification does not affect other endogenous FcRs dependent upon functional FcRγ-chain molecules. Further, in various embodiments, the modification does not affect the assembly of a functional receptor complex involving an FcγR α-chain and the endogenous FcR γ-chain, which is believed to be required for proper expression of some FcγRα-chains on the cell surface and for downstream signaling resulting from an activated receptor. Because the FcR γ-chain is not deleted, in various embodiments animals containing a replacement of endogenous FcγR α-chain genes with human FcγR α-chain genes should be able to process normal effector functions from antibodies through binding of the Fc portion of IgG immunoglobulins to the human FcγR α-chains present on the surface of accessory cells.
[0085] Aschematic illustration (not to scale) of a deletedendogenous lowaffinitymouseFcγRgene is provided inFigure 4 (top). As illustrated, low affinity human FcγR genes FcγRIIA and FcγRIIIA are inserted into the deleted endogenous low affinity mouse FcγR gene locus by a targeting construct (Human FcγRIIIA-IIATargeting Vector) with a genomic fragment containing thehuman lowaffinityhumanFcγRIIAandFcγRIIIAgenes.Eachof thesegenes comprise theα-chainor ligand- binding domain of the human FcγR genes responsible for the binding the Fc portion of an antibody molecule.
[0086] A genetically modified mouse that expresses low affinity human FcγR genes at the endogenous low affinity mouse FcγR locus can be made by any method known in the art. For example, a targeting vector can be made that introduces lowaffinity humanFcγRgenes (e.g., FcγRIIAandFcγRIIIA)with a selectablemarker gene. Figure 4 illustrates a mouse genome comprising a deletion of the endogenous low affinity FcgR locus (top). As illustrated, the targeting construct contains a 5’ homology arm containing sequence upstream of the endogenous low affinity mouse FcγR locus, followed by a drug selection cassette (e.g., a hygromycin resistance gene flanked on both sides by loxP sequences), a genomic fragment containing a human FcγRIIA gene, humanHSP76 gene and human FcγRIIIA gene, and a 3’ homology arm containing sequence downstream of the endogenous low affinity mouse FcγR locus. Upon homologous recombina- tion at the deleted locus, the drug selection cassette is replaced by the sequence contained in the targeting vector (bottom ofFigure4).Theendogenous lowaffinityFcγRgene locus is thus replacedwith lowaffinityhumanFcγRgenes resulting ina cell or animal that expresses low-affinity human FcγR genes. The drug selection cassette may optionally be removed by the subsequent addition of a recombinase (e.g., by Cre treatment).
[0087] Forexpressionof hFcγRIIAonplatelets, the targetingconstructHumanhFcγRIIA ‑IIATargetingVector comprises an extended sequence that includes, e.g., all or substantially all of the human promoter region operably linked to the hFcgRIIAgene in ahumangenome.For preventingexpression of hFcγRIIAonplatelets, the targeting construct lacksall or substantially all of the human promoter region operably linked to the hFcγRIIA gene in a human.
[0088] Further modifications to the chimeric locus (bottom of Figure 4) can be achieved using similar techniques as described for replacementwith twohumanFcγRgenes.Themodification to replace theendogenous lowaffinityFcγRgene locus with two human FcγR genes can further provide a starting point for incorporation of other low affinity human FcγR genes. For example, a schematic illustration (not to scale) of an endogenous low affinity FcγR locus replaced with two human lowaffinity FcγRgenes is provided inFigure 6 (top). As illustrated, lowaffinity humanFcγRgenesFcyRIIB, FcγRIIC andFcγRIIIB are inserted into themodified endogenous lowaffinitymouseFcγRgene locusbyanother targeting construct (Human FcγRIIB-IIIB-IIC Targeting Vector) with a genomic fragment containing the low affinity human FcyRIIB, FcγRIIC and FcγRIIIB genes. Each of these genes comprise the α-chain or ligand-binding domain of the human FcγR genes responsible for the binding the Fc portion of an antibody molecule.
[0089] A genetically modified mouse that expresses five low affinity human FcγR genes at the endogenous low affinity mouse FcγR locus can be made by any method known in the art. For example, a targeting vector can be made that introduces low affinity human FcγR genes (e.g., FcγRIIB, FcγRIIC and FcγRIIIB) with a selectable marker gene. Figure 6 illustrates a mouse genome comprising a replacement of the endogenous low affinity FcγR locus with two low affinity humanFcγRgenes (top).As illustrated, the targeting construct containsa5’ homologyarmcontainingsequenceupstream of the endogenous low affinitymouse FcγR locus, followed by a drug selection cassette (e.g., a neomycin resistance gene flanked on both sides by loxP sequences), a genomic fragment containing a human FcγRIIB gene, a human FcγRIIIB, a human HSP77 gene, a human FcγRIIC gene, followed by a 3’ homology arm containing sequence upstream of the low affinity human FcγRIIIA gene present at the endogenous locus. Upon homologous recombination at themodified locus, a humanFcγRIIB,FcγRIIIBandFcγRIICgeneare inserted5’ to thehumanFcγRIIIAandFcγRIIAgenespreviously present at the endogenous low affinity FcγR gene locus by the sequence contained in the targeting vector (bottom of Figure 6). The 11 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 modifiedendogenous lowaffinityFcγRgene locus is thus furthermodified to incorporate threeadditional lowaffinityhuman FcγR genes resulting in a cell or animal that expresses five low-affinity human FcγR genes. The drug selection cassette mayoptionally be removedby the subsequent addition of a recombinase (e.g., byCre treatment). Figure 6 (bottom) shows the structure of the resulting locus, which will express five low affinity human FcγR genes that can be detected on the surface of accessory cells of the animal’s immune system and independently associate, as appropriate, with an endogenous FcRγ-chain. Experimental Models of FcyR Deficient Mice and FcγR Humanized Mice
[0090] Genetically modified non-human animals that do not express endogenous low affinity mouse FcγR genes are useful,e.g., to elucidate the various functions of the individual lowaffinity FcγRgenes in the immune response, tomeasure the efficacy of a human therapeutic antibody via cell-mediated immunity (e.g., ADCC), to determine an FcγR’s role in immune diseases or disorder, to serve asmodels of immune diseases or disorders, to generate antibodies against one or more FcγR proteins, and to serve as breeding mates to generate other genetically modified mice of interest.
[0091] In one embodiment, a mouse according to the invention can be used to determine a cytotoxic effect lost (in comparison to a wild type mouse) by a mouse that does not express low affinity FcγR genes by administering an agent to such a mouse, where the agent is known to trigger an FcγR-dependent cytotoxic effect in wild type mice. In one embodiment, a mouse of the present invention is implanted with tumor cells and, after a subsequent period of time, injected with an antibody specific for an antigen expressed on the surface of the tumor cells. The isotype of the antibody is known prior to injection and the animals are analyzed for impairment of FcγR-dependent ADCC by comparison to ADCC observed in wild type animals.
[0092] In another aspect,mice deficient in endogenous lowaffinity receptors could be combined (e.g., by breeding) with other immune deficient mice to develop in vivo models of autoimmune disease. For example, Severe Combined Immunodeficiency (SCID) mice are routinely used in the art as model organisms for studying the immune system. SCID mice have an impaired ability to make Tor B lymphocytes, or activate some components of the complement system, and cannot efficiently fight infections, reject tumors, and reject transplants. Low affinity FcγR α-subunit gene-deficient mice of the present inventionmaybe bred toSCIDmice to ascertain cell depletion in a host animal in response to administration of an antibody therapeutic (e.g., an anti-tumor antibody), which would determine the roles of ADCC and complement- dependent cytotoxicity (CDC) in tumor cell depletion in vivo.
[0093] In another aspect, genetically modified non-human animals comprising a replacement of the endogenous low affinity FcγR genes with low-affinity human FcγR genes are provided. Such animals are useful for studying the pharmacokinetics of fully human antibodies and hFcγR-mediated ADCC. In addition, human FcγR genes have been shown to exhibit polymorphisms or allelic variants associated with disease (e.g., SLE, RA, Wegener’s granulomatosis, Guillain-Barré syndrome and Multiple Sclerosis). Thus, genetically modified non-human animals that comprise a replacement of the endogenous low affinity FcγR genes with specific allelic or polymorphic forms of human FcγR genes can be used to study human autoimmune diseases, and traits associated with the polymorphisms, in the animal. In a specific embodiment, the allelic forms of human FcγR genes are associated with enhanced efficacy for human IgG.
[0094] In another specific embodiment, the affect of a human low affinity FcγRpolymorphismon the efficacy of a human antibody therapeutic is determined. In a specific embodiment, an anti-tumor antibody is administered to a first humanized mouse comprising a first polymorphism of a human FcγR and also to a second humanized mouse comprising a second polymorphism of a human FcγR, wherein the first and the second mice each comprise a human tumor cell; and the anti- tumor activity of the anti-tumor antibody is assessed in the firstmouse and in the secondmouse. In a specific embodiment, a treatment option is selected by a physician with respect to treating a human having the first or the second polymorphism andhavinga tumor corresponding to thehuman tumor cell, basedon theassessment of efficacyof the anti-tumor antibody in the first mouse and in the second mouse.
[0095] Suitable polymorphisms of human FcγR genes include all those known in the art. For the human FcγRIIA gene, polymorphisms include, e.g., the high responder and low responder phenotype reported by the ability of T cells to proliferate in response to IgG. The high responder polymorphism is characterized by an arginine residue at position 131 (131Arg)while the low responder is characterizedbyahistidine residueatposition131 (131His). In aspecificembodiment, the human FcγRIIA sequence comprises the 131His polymorphism. A representative protein sequence of the human FcγRIIA α-chain is shown in SEQ ID NO:32.
[0096] Single-nucleotide substitutionsof the humanFcγRIIBgene result inmis-sense substitutions in the ligand-binding domain (α-chain) and putatively affect the binding ability of an Fc portion of an IgG to bind to the α-chain of FcγRIIB on the cell surface. For example, substitution of a threonine residue for an isoleucine at position 232 (Ile232Thr) within the transmembrane domain of the FcγRIIB gene in mice has been shown to impair the signaling ability of the receptor. In a specific embodiment, the human FcγRIIB gene comprises the isoleucine variant (232Ile). A representative protein sequence of the human FcγRIIB α-chain is shown in SEQ ID NO:33.
[0097] Allelic variants of the human FcγRIIIA gene are proposed to be involved in susceptibility to SLE and RA. This 12 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 allelic variant includes a phenylalanine substitution for valine at position 158 (Val158Phe). The valine allelic variant (158Val) is characterized to have a higher affinity for IgG1 and IgG3 than the phenylalanine allelic variant (158Phe). The 158Pheallelic variant has been proposed to lead to a reduced clearance of immune complexes. In a specific embodiment, thehumanFcγRIIIAgenecomprises the158Valallelic variant.A representativeprotein sequenceof thehumanFcγRIIIAα- chain is shown in SEQ ID NO:35.
[0098] Allelic variants of thehumanFcγRIIIB gene include theneutrophil antigen1 (NA1) andneutrophil antigen2 (NA2) alleles. These allelic variants have been proposed to be involved in blood-transfusion reactions, alloimmune neutropae- nia, SLE and Wegener’s granulomatosis. The NA2 allelic variant is characterized by a diminished ability to mediate phagocytosis. In a specific embodiment, the human FcγRIIIB gene comprises the NA2 allelic variant. A representative protein sequence of the human FcγRIIIB α-chain is shown in SEQ ID NO:36.
[0099] In one aspect, the genetically modified non-human animals are useful for optimizing FcγR-mediated functions triggeredby theFcportionof therapeutic antibodies. TheFc regionsof antibodies canbemodifiedbyanymethodknown in theart. For example, aminoacid residueswithin theFcportion (e.g.,CH2andCH3domains) canbemodified to selectively enhance the binding affinity to human FcγRIIIA. Thus, the resulting antibody should have enhanced FcγRIIIA-dependent ADCC. In a specific embodiment, an animal expressing human FcγRIIIA of the present invention is used to evaluate the enhancedADCCability of amodifiedhumanantibodybyadministeringamodifiedhumanantibody to theanimal, detecting (e.g., in vitro) antibody binding to FcγRIIIA-expressing cells and comparing the ADCC activity observed to the ADCC activity observed from that determined in a wild type animal. EXAMPLES Example 1: Generation of Low Affinity FcγR Gene Deficient Mice
[0100] A targeting construct for introducing a deletion of the endogenous low affinity mouse FcγR locus (described below) was constructed (Figure 1).
[0101] The targeting construct was made using VELOCIGENE® technology (see, e.g., US Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652‑659) to modify the Bacterial Artificial Chromosome (BAC) RP23‑395f6 (Invitrogen). RP23‑395f6 BACDNAwasmodified to delete the endogenous low affinity FcγRIIB, FcγRIVand FcγRIII genes comprising the α-chain of each of the FcγRs.
[0102] Briefly, upstream and downstream homology arms were made employing primers mFcR 5-up‑1 (5’-ACCAG- GATAT GACCTGTAGA G; SEQ ID NO:1) and mFcR 3-up‑1a (GTCCATGGGT AAGTAGAAAC A; SEQ ID NO:2), and mFcR 5-DN (ATGCGAGCTC ATGCATCTATG TCGGGTGCGG AGAAAGAGGTAATGCATTCT TGCCCAATAC TTAC; SEQ ID NO:3) and mFcR 3-DN (ACTCATGGAG CCTCAACAGG A; SEQ ID NO:4), respectively. These homology arms were used tomake a cassette that deleted theα-chains of the endogenous lowaffinity FcγRIIB, FcγRIVandFcγRIII genes. The targeting construct included a loxed neomycin resistance gene comprising homology arms comprising sequence homologous to a 5’ and a 3’ region with respect to the endogenous locus. Genes and / or sequences upstream of the endogenous FcγRIIB gene and downstream of the endogenous FcγRIII gene (see Figure 1) were unmodified by the targeting construct.
[0103] The targeted deletion was confirmed by polymerase chain reaction (PCR) using primers outside the deleted regionandwithin the targeting construct. Theupstream regionof the deleted locuswasconfirmedbyPCRusingprimers to mFcR-up-detect (ATCCTGAGTA TACTATGACA AGA; SEQ ID NO:5) and PGK-up-detect (ACTAGTGAGA CGTGCTACTT C; SEQ ID NO:6), whereas the downstream region of the deleted locus was confirmed using primers pA-DN-detect (CTCCCACTCATGATCTATAGA; SEQ IDNO:7) andmFcR-DN-detect (TGGAGCCTCAACAGGACTCC A; SEQ ID NO:8). The nucleotide sequence across the upstream deletion point included the following, which indicates endogenous mouse sequence downstream of the FcγRIIB gene (contained within the parentheses below) linked contiguously to cassette sequence present at the deletion point: (GTCCATGGGT AAGTAGAAAC A)TTCGCTACC TTAGGACCGTTA(SEQIDNO:9).Thenucleotidesequenceacross thedownstreamdeletionpoint included the following, which indicates cassette sequence contiguous with endogenous mouse sequence upstream of the FcγRIII gene (contained within the parentheses below): CGGGTGCGGA GAAAGAGGTA AT(GCATTCTT GCCCAATACT TA) (SEQ ID NO:10).
[0104] Mice deficient in FcγRIIB, FcγRIII and FcγRIV were generated through electroporation of a targeted BAC DNA (described above) into mouse ES cells. Positive ES cells clones are confirmed by Taqman™ screening and karyotyping. Positive ES cell clones were then used to implant female mice to give rise to a litter of pups deficient in low affinity FcγR genes. 13 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 Example 2: Characterization of Low Affinity FcγR Gene Deficient Mice
[0105] Spleenswereharvested fromFcγRdeficient andwild typemiceandperfusedwith10mLCollagenase-D in sterile disposablebags.Eachbagcontaininga single spleenwas thenplaced intoaStomacher® (Seward) andhomogenizedat a mediumsetting for 30seconds.Homogenizedspleenswere transferred to10cmpetri dishesand incubated for 25minutes at 37°C. Cells were separated with a pipette using a 1:50 dilution of 0.5 M EDTA, followed by another incubation for five minutesat 37°C.Cellswere thenpelletedwithacentrifuge (1000 rpm for10minutes) and redbloodcellswere lysed in4mL ACK buffer (Invitrogen) for three minutes. Splenocytes were diluted with RPMI‑1640 (Sigma) and centrifuged again. Pelleted cells were resuspended in 10mL RPMI‑1640 and filtered with a 0.2 µm cell strainer.
[0106] FlowCytometry.Lymphocytecell populationswere identifiedbyFACson theBDLSR IISystem(BDBioscience) with the following flourochrome conjugated cell surface markers: anti-CD19 (B cells), anti-CD3 (Tcells), anti-NKp46 (NK cells) and anti-F4 / 80 (macrophages). Lymphocytes were gated for specific cell lineages and analyzed for expression of endogenous FcγRIII and FcγRIIB with a rat anti-mouse FcγRIII / II antibody (clone 2.4G2, BD Biosciences). Clone 2.4G2 recognizes a common polymorphic epitope on the extracellular domains of murine FcγRIII and FcγRII. The results show that therewas no detectablemurine lowaffinity FcγRIII or FcγRII onB-cells, NK cells andmacrophages inmFcγRKOmice (Figure 2).
[0107] ADCCAssay.Splenocytes isolated fromFcγRgene deficient andwild typemicewere analyzed for their ability to perform ADCC in a cell-killing assay. Cell populations were isolated and separated using MACS® Technology (Miltenyi Biotec). Briefly, T-cells were depleted from splenocytes using magnetically labeled anti-mouse CD3 beads. The T-cell depleted splenocytes were then enriched for NK cells using magnetically labeled anti-mouse CD49B beads. Separately, Raji cells (expressing human CD20) were coated with varying concentrations (ranging from 0.1 to 10 µg / mL) of mouse anti-human CD20 antibody (Clone B1; Beckman Coulter) for 30 minutes at 4°C. The antibody-coated Raji cells were incubatedwith the enrichedNK cells at ratios (NK:Raji) of 100:1 and 50:1 for four hours at 37°C. Cell deathwasmeasured using the CytoTox-Glo™Cytotoxicity Assay (Promega). Luminescence signal is derived from lysed cells and proportional to the number of dead cells. Luminescence from controls (no anti-CD20 antibody) was determined for background dead cell count for each ratio and subtracted frommeasurements for wild type and KOmice. Average cell death was calculated and percent decrease in cell killing (% ADCC) was determined by comparison to wild type. Results are shown in Table 1. Table 1 mFcγR KO % ADCC 10 µg / mL B1 Antibody 1 µg / mL B1 Antibody 0.1 µg / mL B1 Antibody NK cell:Raji cell 100:1 42 53 35 50:1 15 0 0 Example 3: In Vivo Depletion of B cells in Low Affinity FcγR Gene Deficient Mice
[0108] The effect of human or murine Fc isotypes on B cell depletion through the ADCC pathway was determined for various B cell compartments in low affinity FcγR gene deficient mice engineered to express human CD20 using a human anti-humanCD20antibody.Miceexpressing humanCD20were separately engineeredusing techniques known in theart. Mice that express humanCD20 on B cells and deficient in low affinity FcγRgenes (described in Example 1) weremade by standard breeding techniques of the two engineered strains.
[0109] Separategroupsofmice thatexpressedhumanCD20andhada full complementof endogenous lowaffinityFcγR genes were each administered one of the following: (1) 10 mg / kg control antibody (N=4; human antibody not specific for human CD20 having amouse IgG2a); (2) 2 mg / kg Ab 168 (N=3; human anti-hCD20 antibody with amouse IgG2a; heavy and light chain variable region sequences found in SEQ ID NOs: 339 and 347, respectively, of US Patent Publication No. 2009 / 0035322); (3) 10mg / kgAb168; (4) 2mg / kgAb735 (N=3;Ab168with human IgG1); (5) 10mg / kgAb735. In a similar set of experiments, groups of mice that expressed human CD20 and had a deletion of the endogenous low affinity FcγR genes were administered the control and human anti-hCD20 antibodies (described above).
[0110] Mice in each group were administered the antibodies by intra-peritoneal injections. Seven days post-injection, animals were euthanized and the remaining B cell contents of bone marrow (B220+ / IgM+), peripheral blood (B220+ / CD19+), lymph node (B220+ / CD19+) and spleen (B220+ / CD19+) were identified by multi-color FACS performed on a LSR-II flow cytometer and analyzed using Flow-Jo software (as described above). The results of the B cell depletion experiments are shown in Figures 3A‑3D.
[0111] As shown in Figures 3A‑3D, Ab 735 depleted B cells with a lower efficiency than Ab 168 in mice containing a complete complement of lowaffinity FcγRgenes. Further, for both antibodies (mouse and humanFc), B cell depletionwas significantly reduced in mice lacking a complete complement of low affinity FcγR genes. This Example shows that the 14 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 ability to deplete B cells through the ADCC pathway requires low affinity FcγRs and demonstrate that measuring ADCC efficiency for antibodies containing human constant regions in mice is more suitable by the use of genetically engineered mice containing a full complement of human low affinity FcγR genes. Example 4: Generation of FcγRIIIA / FcγRIIA Humanized Mice
[0112] A targeting construct for introducing two low affinity human FcγR genes into a deleted endogenous low affinity mouse FcγR locus (described below) was constructed (Figure 4).
[0113] A targeting construct comprising human FcγRIIA and FcγRIIIA genes was made using similar methods (see Example 1) through modification of BAC RP23‑395f6 and CTD‑2514j12 (Invitrogen). BAC DNA of both BACs was modified to introduce a deletion of the α-chains of the low affinity human FcγRIIA and FcγRIIIA genes into the deleted endogenous low affinity FcγR locus.
[0114] In a similar fashion, upstream and downstream homology arms were made employing primers h14 (GCCAGC- CACA AAGGAGATAA TC; SEQ ID NO:11) and h15 (GCAACATTTA GGACAACTCG GG; SEQ ID NO:12), and h4 (GATTTCCTAACCACCTACCCC; SEQ IDNO:13) and h5 (TCTTTTCCAATGGCAGTTG; SEQ IDNO:14), respectively. These homology arms were used to make a cassette that introduced the α-chains of low affinity human FcγRIIA and FcγRIIIA genes into the endogenous mouse low affinity FcγR locus. The targeting construct included a 5’ homology arm including sequence 5’ to the deleted endogenous low affinity FcγR locus, a FRT’ed hygromycin resistance gene, followed by a human genomic fragment from BAC CTD‑2514j12 comprising low affinity human FcγRIIA and FcγRIIIA α-chain genes, anda3’ homologyarmcomprisingmousesequence3’ to thedeletedendogenous lowaffinityFcγR locus (middle of Figure 4). For a mouse that expresses FcγRIIA on mouse platelets, a targeting construct was made in a similar manner (using the sameBACs) except that the construct comprisesanextendedpromoter sequenceoperably linked to thehuman FcγRIIA gene in the human genome, e.g., up to about 18 kb or more, using a hygromycin cassette that is flanked on both sides by lox2372 sites, wherein the junction of the promoter region and the first lox 2372 site is ATCGGGGATA GAGATGTTTG(CC)GCGATCGCGGTACCGGGC(SEQ IDNO:37human / lox2372 junction inparentheses) andwherein the junction of the second lox2372 site and mouse sequence is TTATACGAAG TTATACCGG(T G)CATTCTTGC CCAATACTTA (SEQ ID NO:38 lox2372 / mouse junction in parentheses). Suitable primers were used to genotype the humanization comprising the promoter region.
[0115] Targeted insertion of the human FcγRIIA and FcγRIIIA α-chain genes was confirmed by PCR (as described above). The upstream region of the partially humanized locus was confirmed by PCR using primers h16 (CCCAGGTAAG TCGTGATGAA ACAG; SEQ ID NO:15) and pA-DN-detect (CTCCCACTCATGATCTATAG A; SEQ ID NO:16), whereas thedownstreamregionof thepartially humanized locuswasconfirmedusingprimersmFcRDN-detect‑9 (TGGAGCCTCA ACAGGACTCCA; SEQ IDNO:17) and h6 (CACACATCTCCTGGTGACTTG;SEQ IDNO:18). The nucleotide sequence across the downstream junction included the following, which indicates a novel insertion point of endogenous human sequence upstream of the hFcγRIIA gene (contained within the parentheses below) contiguous with endogenousmouse sequence 3’ of the deleted low affinity FcγR locus: (CAACTGCCAT TGGAAAAGA)C TCGAGTGCCATTTCATTACC TC (SEQ ID NO:19). The upstream junction includes two novel sequences. One point of the upstream junction includes the following, which indicates nucleotide sequence of the hygromycin cassette contiguous with human genomic sequence (contained within the parentheses below) that comprises the upstream region of the inserted hFcγRIIIA gene: TAAACCCGCG GTGGAGCTC(G CCAGCCACAA AGGAGATAAT CA) (SEQ ID NO:20). The second point of the upstream junction includes the following, which indicates a nucleotide sequence of an endogenous mouse sequence (containedwithin theparenthesesbelow) from theupstream regionof the deleted lowaffinity FcyR locus contiguouswith a nucleotide sequence within the hygromycin cassette: (CCATGGGTAAGTAGAAAC)TC TAGACCCCCGGGCTCGATAA CT (SEQ ID NO:21).
[0116] Mice containing two lowaffinity humanFcγRgenes (hFcγRIIA, lackingextendedpromoter region, andhFcγRIIIA) in place of the endogenous low affinity mouse FcγR locus were generated through electroporation of the targeted BAC DNA (described above) into mouse ES cells. Positive ES cells clones were confirmed by Taqman™ screening and karyotyping. Positive ES cell clones were then used to implant female mice using the VELOCIMOUSE® method (described below) to generate a litter of pups containing a replacement of the endogenous low affinity FcγR genes with the two human low affinity FcγR genes.
[0117] Targeted ES cells described above were used as donor ES cells and introduced into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (see, e.g., US Pat. No. 7,294,754 and Poueymirou et al. (2007) F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses Nature Biotech. 25(1):91‑99. VELOCIMICE® (F0 mice fully derived from the donor ES cell) bearing hFcγRIIA and hFcγRIIIA were identified by genotyping using a modification of allele assay (Valenzuela et al., supra) that detected the presence of the hFcγR genes.
[0118] Mice bearing the hFcγR genes can be bred to a Cre deleter mouse strain (see, e.g., International Patent Application Publication No. WO 2009 / 114400) in order to remove any loxed neo cassette introduced by the targeting 15 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 construct that is not removed,e.g., at theEScell stageor in theembryo.Optionally, theneomycin cassette is retained in the mice.
[0119] Pups are genotyped and a pup heterozygous for the hFcγR genes is selected for characterizing FcγRIIA and FcγRIIIA humanizations. Example 5: Characterization of FcγRIIIA / FcγRIIA Humanized Mice
[0120] Spleens were harvested from humanized FcγRIIIA / FcγRIIA (heterozygotes, lacking the extended FcγRIIA promoter region) and wild type mice and prepared for FACs (as described above).
[0121] Flow Cytometry. Lymphocytes were gated for specific cell lineages and analyzed for expression of hFcγRII and hFcγRIII using a mouse anti-human FcγRII antibody (Clone FLI8.26; BD Biosciences) and a mouse anti-human FcγRIII antibody (Clone 3G8; BD Biosciences), respectively. Relative expression (++, +) or no expression (‑) observed for each lymphocyte subpopulation is shown in Table 2. Table 2 Lymphocyte Lineage hFcγRIII hFcγRII B cells - - NK cells ++ - Macrophages + + Neutrophils - +
[0122] In a similar experiment, spleens were harvested from humanized FcγRIIIA / FcγRIIA (homozygotes, lacking the extendedFcγRIIA promoter region) andwild typemice and prepared for FACs (as described above). Results are shown in Figures 5A and 5B. Percent of separate lymphocyte cell populations expressing human FcγRIIIA, FcγRIIA or both in FcγRIIIA / FcγRIIA homozygote mice is shown in Table 3. Table 3 Lymphocyte Lineage hFcγRIII hFcγRII hFcγRII / hFcγRII NK cells 97 - - Macrophages 26 14 39 Neutrophils - 94 -
[0123] As shown in this Example, geneticallymodifiedmice (both heterozygote and homozygote genotypes) generated in accordance with Example 3 expressed human FcγRIIIA on NK cells and macrophages; and human FcγRIIA on neutrophils and macrophages, but not platelets. Human FcγRIIIA was highly expressed on NK cells. The expression pattern of human FcγR genes shown in this Example is consistent with the expression patterns of these genes in human accessory cells. Example 6: Generation of Low Affinity FcγR Humanized Mice
[0124] A targeting construct for introducing three additional low affinity human FcγR genes into a partially humanized endogenous low affinity FcγR locus (described below) was constructed (Figure 6).
[0125] A targeting construct comprising human FcγRIIB, FcγRIIIB and FcγRIIC genes wasmade using similar methods (see Example 1) through modification of BAC RP‑23 395f6 and RP‑11 697e5 (Invitrogen). BAC DNA of both BACs was modified to introduce the α-chains of the low affinity human FcγRIIB, FcγRIIIB and FcγRIIC genes into the partially humanized endogenous low affinity FcγR locus containing two human low affinity FcγR genes.
[0126] In a similar fashion, upstream and downstream homology arms were made employing primers mFcR up‑1 (ACCAGGATAT GACCTGTAGA G; SEQ ID NO:22) and mFcR2b Nhel‑2 (GTTTCTACTT ACCCATGGAC; SEQ ID NO:23), and h10 (AAATACACAC TGCCACAGAC AG; SEQ ID NO:24) and h11 (CCTCTTTTGT GAGTTTCCTG TG; SEQ ID NO:25), respectively. These homology arms were used to make a cassette that introduced DNA sequences encoding theα-chainsof lowaffinityhumanFcγRIIB,FcγRIIIBandFcγRIIC.The targetingconstruct includeda5’ homology arm including mouse sequence 5’ to the deleted endogenous low affinity FcγR locus, a loxed neomycin resistance gene, followed by a human genomic fragment from BAC RP‑11 697e5 comprising low affinity human FcγRIIB, FcγRIIIB and 16 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 FcγRIICα-chain genes, and a 3’ homology arm comprising human sequence 5’ to the low affinity human FcγRIIIAα-chain gene (middle of Figure 6).
[0127] Targeted insertion of three additional low affinity human FcγR genes was confirmed by PCR (as described above). The upstream region of the fully humanized locus was confirmed by PCR using primers mFcR up-detect‑3 (GAGTATACTA TGACAAGAGC ATC; SEQ ID NO:26) and PGK up-detect (ACTAGTGAGA CGTGCTACTT C; SEQ ID NO:27), whereas the downstream region of the fully humanized locus was confirmed using primers neo detect (CTCCCACTCA TGATCTATAG A; SEQ ID NO:28) and h12 (CTTTTTATGG TCCCACAATC AG; SEQ ID NO:29). The nucleotide sequence across the downstream junction included the same human genomic sequence upstream of the hFcγRIIAα-chain gene (seeExample 3; SEQ IDNO:19). The nucleotide sequence across the upstream junction included the following, which indicates two novel junctions of mouse and cassette sequences and cassette and human genomic sequences at the insertion point. The junction of genomicmouse sequence (containedwithin the parentheses below) and the upstream region of the neo cassette sequence is: (GTCCATGGGTAAGTAGAAAC A)TTCGCTACC TTAGGACCGT TA (SEQ ID NO:30). The second novel junction includes the joining of the 3’ end of neo cassette (contained within the parentheses below) and a human genomic sequence downstream of the hFcgRIIB α-chain gene: (GCTTATCGAT ACCGTCGAC)A AATACACACT GCCACAGACA GG; SEQ ID NO:31). These junctions are show in Figure 6 (middle) within the targeting construct. The resulting modified genome of the fully humanized low affinity FcγR locus is shown in Figure 6 (bottom).
[0128] Mice containing five low affinity human FcγR genes in place of the endogenous low affinity mouse FcγR locus weregenerated throughelectroporationof the targetedBACDNA(describedabove) intomouseEScells.PositiveEScells cloneswere confirmed by Taqman™ screening and karyotyping. Positive ES cell clones were then used to implant female mice (as described above) to give rise to a litter of pups containing a replacement of the endogenous low affinity FcγR genes for five human low affinity FcγR genes. Example 7: Characterization of Low Affinity FcγR Humanized Mice
[0129] Spleens were harvested from fully humanized FcγR (heterozygotes) and wild type mice and prepared for FACs (as described above).
[0130] Flow Cytometry. Lymphocytes were gated for specific cell lineages and analyzed for expression of human FcγRIIA and FcγRIIIA using a mouse anti-human FcγRII antibody (Clone FLI8.26; BD Biosciences) and a mouse anti- human FcγRIII antibody (Clone 3G8; BD Biosciences), respectively. Relative expression (++, +) or no expression (‑) observed for each lymphocyte subpopulation is shown in Table 4. Table 4 Lymphocyte Lineage hFcγRIII hFcγRII B cells - + NK cells + + Macrophages + + Neutrophils + +
[0131] In a similar experiment, spleens were harvested from fully humanized FcγR (homozygotes) and wild type mice and prepared for FACs (as described above). Results are shown in Figure 7. Percent of separate lymphocyte cell populations expressing human FcγRIIIA, human FcγRIIIB, human FcγRIIA, human FcγRIIB, human FcγRIIC or a combination thereof in fully humanized FcγR homozygote mice is shown in Table 5. Table 5 Lymphocyte Lineage hFcγRIII hFcγRII hFcγRII / hFcγRIII B cells 100 NK cells 30 - - Macrophages <1 55 26 Neutrophils - 100
[0132] As shown in this Example, geneticallymodifiedmice (both heterzyogote and homozygote genotypes) generated in accordancewith Example 5 expressed humanFcγRIIIA onNK cells andmacrophages, humanFcγRIIIB on neutrophils, 17 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 human FcγRIIA on neutrophils and macrophages, human FcγRIIB on B cells, and human FcγRIIC on NK cells. The expression pattern of human FcγRgenes shown in this Example is consistent with the expression patterns of these genes in human accessory cells. Example 8: ADCC in Humanized FcγR Mice
[0133] Splenocytes isolated from FcγR gene deficient (i.e. knockout), FcγRIIIA / FcγRIIA (homozygotes), FcγRIIIA / Fc- γRIIIB / FcγRIIA / FcγRIIB / FcγRIIC (homozygotes) and wild type mice were analyzed for their ability to perform ADCC in a cell-killing assay (as described above in Example 2).
[0134] Briefly, cell populations were isolated and separated usingMACS® Technology (Miltenyi Biotec). Briefly, Tand B cell depleted splenocytes were cultured for twoweeks in the presence ofmouse IL‑2 (500U / mL). The resulting expanded NKcellswere usedas effector cells in theADCCassays at a ratio of 50:1 (NK:Raji). Raji cellswere coatedwith 10 ug / mLof Ab 168 or Ab 735 (as described above in Example 3). Results are shown in Table 6. Table 6 % ADCC NK Cell Genotype 10 µg / mL Ab 168 10 µg / mL Ab 735 Wild Type 89 72 Mouse FcγR KO 13 14 Human FcγRIIIA-IIA HO 78 85 Human FcγRIIIA-IIIB-IIA-IIB-IIC HO 81 59
[0135] The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Numbered further Embodiments
[0136] 1. A mouse comprising a genetic modification, wherein the genetic modification comprises a replacement of endogenous low affinity FcγR genes with at least two low affinity human FcγR genes placed at the endogenous mouse low affinity FcγR gene locus, and wherein the mouse comprises a functional FcR γ-chain. 2. The mouse of item 1, wherein the at least two low affinity human FcγR genes are selected from FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB. 3. The mouse of item 1, wherein the at least two low affinity human FcγR genes are FcγRIIA and FcγRIIIA. 4. The mouse of item 3, wherein the human FcγRIIIA is expressed on NK cells of the mouse. 5. The mouse of item 1, wherein the at least two low affinity human FcγR genes are FcγRIIB, FcγRIIC, and FcγRIIIB. 6. The mouse of item 3, wherein the FcγRIIA and FcγRIIIA genes comprise allelic variants or polymorphisms. 7. Themouse of item 5, wherein themouse comprises human low affinity FcγRallelic variants, and the allelic variants are selected from the group consisting of (a) FcγRIIA allelic variant 131H, (b) FcγRIIIA allelic variant 158V, (c) FcγRIIB allelic variant 232I, (d) FcγRIIIB allelic variant characterized by a neutrophil antigen 2 (NA2) allele, and, (e) a combination thereof. 8. A genetically modified mouse, wherein the genetic modification comprises a replacement of endogenous mouse genes encoding FcγRIIB, FcγRIII, and FcγRIVα-subunits with a gene encoding a human FcγRIIIAα-subunit, wherein the mouse expresses a human FcγRIIIA protein associated with an endogenous mouse FcR γ-subunit, wherein the human FcγRIIIA protein is expressed on the surface of a mouse NK cell. 18 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 9. The genetically modifiedmouse of item 8, wherein mouse NK cell is a circulating NK cell in the blood of themouse, and the FcγRIIIA protein expressed on the surface of themouse NK cell binds an immunoadhesin or an antibody that comprisesahumanFcor amodifiedhumanFc,wherein the immunoadhesinor antibodyspecifically bindsa target cell in themouse, and binding of the immunoadhesin or the antibody to the FcγRIIIA of theNK cell mediates NK cell killing of the target cell. 10. The genetically modified mouse of item 9, wherein the target cell is infected with a human pathogen, and the immunoadhesin or antibody specifically binds an epitope of the human pathogen. 11. The genetically modified mouse of item 9, wherein the target cell is a tumor cell, and the immunoadhesin or antibody specifically binds an epitope of the tumor cell. 12. A method for measuring therapeutic-dependent cell killing, comprising: (a) administering to a geneticallymodifiedmousea therapeutic agent that specifically binds a target cell that is not an NK cell in the mouse, wherein the therapeutic agent comprises a human Fc; (b) measuring a level of NK-mediated target cell killing in the mouse or in a tissue sample of the mouse; and, (c) determining the amount of target cell killing that is mediated by the therapeutic agent, thereby measuring therapeutic-dependent cell killing; wherein the geneticmodification comprises a deletion of a gene encoding theα-subunit of mouse FcγRIIB, a deletion of a gene encoding theα-subunit ofmouse FcγRIII, and a deletion of a gene encoding theα-subunit ofmouse FcγRIV, and wherein the mouse comprises a gene encoding an α-subunit of a human FcγRIIIA at the endogenous mouse α- subunit locus and wherein the mouse expresses a functional FcR γ-chain subunit. 13. The method of item 12, wherein the mouse further comprises at the endogenous mouse α-subunit locus a gene encoding a human FcγR α-subunit selected from an an FcγRIIA α-subunit , FcγRIIBα-subunit, an FcγRIICα-subunit, an FcγRIIIB α-subunit, and a combination thereof. 14. The method of item 12, wherein the target cell is a human pathogen, and the therapeutic specifically binds an epitope of the human pathogen. 15. Themethod of item 12, wherein the target cell is a mouse cell infected by a human pathogen, and the therapeutic specifically binds an epitope of the human pathogen. 16. Themethod of item 12, wherein the target cell is a human cell infected by a human pathogen, and the therapeutic specifically binds an epitope of the human pathogen. 17. The method of item 12, wherein the target cell is a human tumor cell, and the therapeutic specifically binds an epitope of the human tumor cell. 18. The method of item 12, wherein the tissue sample is a blood sample. 19. The method of item 12, wherein the therapeutic is an antibody. 20. The method of item 17, wherein the antibody is a human antibody. Claims 1. A genetically modified mouse that does not express an endogenous FcyRIIB α-chain, does not express an endogenous FcyRIV α-chain, and does not express an endogenous FcyRIII α-chain. 2. The genetically modified mouse of claim 1, wherein the mouse genome comprises a deletion of an endogenous FcγRIIBα-chain gene, a deletion of anendogenous FcγRIVα-chain gene, and adeletion of an endogenousFcγRIIIα- chain gene. 3. The genetically modified mouse of claim 1 or 2, wherein the mouse comprises a reduced ability to make an immune 19 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 response to an antigen as compared to a wild-type mouse with respect to the same antigen. 4. The genetically modified mouse of any one of claims 1‑3, wherein the mouse comprises at least a 50% reduction in antibody-dependent cell-mediated cytotoxicity (ADCC). 5. The genetically modified mouse of any one of claims 1‑4, wherein the mouse expresses a functional FcR γ-chain. 6. Thegeneticallymodifiedmouseof anyoneof claims 1‑5,wherein themousegenome further comprisesanucleic acid sequence encoding a human CD20 gene, wherein the mouse specifically expresses functional CD20 on B cells. 7. A genetically modified mouse cell whose genome comprises a deletion of an endogenous FcγRIIB α-chain gene, a deletion of an endogenous FcγRIV α-chain gene, and a deletion of an endogenous FcγRIII α-chain gene. 8. The genetically modified mouse cell of claim 7, wherein the genome of the mouse cell encodes a functional FcR γ- chain. 9. The genetically modified mouse cell of claim 7 or 8, wherein the cell is an embryonic stem (ES) cell. 10. A method of making a genetically modified mouse that does not express an endogenous FcyRIIB α-chain, does not express an endogenous FcyRIV α-chain, and does not express an endogenous FcyRIII α-chain, comprising transplanting the mouse ES cell of claim 9 into a recipient mouse embryo; and obtaining a genetically modified mouse whose genome comprises a deletion of the endogenous FcγRIIB α-chain gene, a deletion of the endogenous FcγRIV α-chain gene, and a deletion of the endogenous FcγRIII α-chain gene. 11. The genetically modified mouse cell of claim 7 or 8, wherein the mouse cell is a mouse natural killer (NK) cell. 12. The genetically modified mouse cell of claim 7 or 8, wherein the mouse cell is a mouse B cell. 13. Thegeneticallymodifiedmousecell of claim12,wherein thegenomeof themousecell further anucleic acid sequence encoding a human CD20 gene, wherein the mouse B cell expresses functional CD20. 14. A targeting vector for deletion of endogenous mouse FcγRIIB, FcγRIV and FcγRIII genes, the targeting vector comprising: (i) a 5’ homology armcomprising anucleic acid sequence that is homologous toa genomic sequence that is 5’ to a mouse FcγRIIB gene in an endogenous mouse genome, (ii) a selection cassette, and (iii) a 3’ homology arm comprising a nucleic acid sequence that is homologous to a genomic sequence that is 3’ to a mouse FcγRIII in an endogenous mouse genome. 15. The targeting vector of claim14,wherein the selection cassette is flankedby recombination sites that allowdeletion of the selection cassette upon treatment with an appropriate recombinase. 20 EP 4 706 388 A2 5 10 15 20 25 30 35 40 45 50 55 21 EP 4 706 388 A2 22 EP 4 706 388 A2 23 EP 4 706 388 A2 24 EP 4 706 388 A2 25 EP 4 706 388 A2 26 EP 4 706 388 A2 27 EP 4 706 388 A2 28 EP 4 706 388 A2 29 EP 4 706 388 A2 30 EP 4 706 388 A2 31 EP 4 706 388 A2 32 EP 4 706 388 A2 REFERENCES CITED IN THE DESCRIPTION This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard. Patent documents cited in the description • US 6111166 A
[0073] • US 6676927 B
[0073] • US 7351875 B
[0073] • US 7402728 B
[0073] • US 7416726 B
[0073] • US 6586251 B, Valenzuela
[0101] • US 20090035322 A
[0109] • US 7294754 B, Poueymirou
[0117] • WO 2009114400 A
[0118] Non-patent literature cited in the description • TAKAI et al. FcR γ Chain Depletion Results in Pleiotrophic Effector Cell Defects.Cell, 1994, vol. 76, 519-529
[0071] • VUGTet al.FcR γ-Chain IsEssential forBothSurface Expression and Function of Human FcγRI (CD64) In Vivo. Blood, 1996, vol. 87 (9), 3593-3599
[0071] • PARK et al. Resistance of Fc Receptor-deficient Mice to Fatal Glomerulonephritis. J. Clin. Invest., 1998, vol. 102 (6), 1229-1238
[0071] • BARNES et al. FcyRI-Deficient Mice Show Multiple Alterations to Inflammatory and ImmuneResponses. Immunity, 2002, vol. 16, 379-389
[0071] • TAKAI et al. Augmented humoral and anaphylactic responses in FcgRII-deficient mice. Nature, 1996, vol. 379, 346-349
[0072] • SU et al. Genomic organization of classical human low-affinityFcy receptor genes.Genesand Immunity, 2002, vol. 3 (1), S51-S56
[0073] • HEIJNEN et al. A Human FcgRI / CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics. J. Hematother., 1996, vol. 4, 351-356
[0073] • HEIJNEN ; VAN DE WINKEL. Antigen Targeting to Myeloid-specific Human FcgRI / CD64 Triggers En- hanced Antibody Responses in Transgenic. J. Clin. Invest., 1996, vol. 97 (2), 331-338
[0073] • Nature Biotech., vol. 21 (6), 652-659
[0101] • Nature Biotech., vol. 25 (1), 91-99
[0117] 摘要 提供了遺傳修飾的非人動物和用於產生和使用它們的方法和組 合物,其中所述遺傳修飾包括內源低親和力 FcγR基因座的缺失,並 且其中小鼠能夠表達功能性 FcRγ鏈。描述了遺傳修飾的小鼠,包括 從內源 FcγR基因座表達低親和力人 FcγR基因的小鼠,並且其中所 述小鼠包含功能性 FcRγ鏈。提供了在宿主免疫系統的輔助細胞上表 達至多 5個低親和力人 FcγR基因的遺傳修飾的小鼠。
Claims
1. A genetically modified mouse that does not express an endogenous FcyRIIB α-chain, does not express an endogenous FcyRIV α-chain, and does not express an endogenous FcyRIII α-chain.
2. The genetically modified mouse of claim 1, wherein the mouse genome comprises a deletion of an endogenous FcγRIIB α-chain gene, a deletion of an endogenous FcγRIV α-chain gene, and a deletion of an endogenous FcγRIII α-chain gene.
3. The genetically modified mouse of claim 1 or 2, wherein the mouse comprises a reduced ability to make an immune response to an antigen as compared to a wild-type mouse with respect to the same antigen.
4. The genetically modified mouse of any one of claims 1-3, wherein the mouse comprises at least a 50% reduction in antibody-dependent cell-mediated cytotoxicity (ADCC).
5. The genetically modified mouse of any one of claims 1-4, wherein the mouse expresses a functional FcR γ-chain.
6. The genetically modified mouse of any one of claims 1-5, wherein the mouse genome further comprises a nucleic acid sequence encoding a human CD20 gene, wherein the mouse specifically expresses functional CD20 on B cells.
7. A genetically modified mouse cell whose genome comprises a deletion of an endogenous FcγRIIB α-chain gene, a deletion of an endogenous FcγRIV α-chain gene, and a deletion of an endogenous FcγRIII α-chain gene.
8. The genetically modified mouse cell of claim 7, wherein the genome of the mouse cell encodes a functional FcR γ-chain.
9. The genetically modified mouse cell of claim 7 or 8, wherein the cell is an embryonic stem (ES) cell.
10. A method of making a genetically modified mouse that does not express an endogenous FcyRIIB α-chain, does not express an endogenous FcyRIV α-chain, and does not express an endogenous FcyRIII α-chain, comprising transplanting the mouse ES cell of claim 9 into a recipient mouse embryo; and obtaining a genetically modified mouse whose genome comprises a deletion of the endogenous FcγRIIB α-chain gene, a deletion of the endogenous FcγRIV α-chain gene, and a deletion of the endogenous FcγRIII α-chain gene.
11. The genetically modified mouse cell of claim 7 or 8, wherein the mouse cell is a mouse natural killer (NK) cell.
12. The genetically modified mouse cell of claim 7 or 8, wherein the mouse cell is a mouse B cell.
13. The genetically modified mouse cell of claim 12, wherein the genome of the mouse cell further a nucleic acid sequence encoding a human CD20 gene, wherein the mouse B cell expresses functional CD20.
14. A targeting vector for deletion of endogenous mouse FcγRIIB, FcγRIV and FcγRIII genes, the targeting vector comprising: (i) a 5' homology arm comprising a nucleic acid sequence that is homologous to a genomic sequence that is 5' to a mouse FcγRIIB gene in an endogenous mouse genome, (ii) a selection cassette, and (iii) a 3' homology arm comprising a nucleic acid sequence that is homologous to a genomic sequence that is 3' to a mouse FcγRIII in an endogenous mouse genome.
15. The targeting vector of claim 14, wherein the selection cassette is flanked by recombination sites that allow deletion of the selection cassette upon treatment with an appropriate recombinase.
